Apr 132 minMursla unveils new bead-nanochip technology for ultrasensitive and high throughput exosome detectionNovel technology further establishes Mursla’s capabilities to uniquely analyse exosome biology for clinical translation
Mar 293 minMursla gains mentorship from Roche Diagnostics for pilot study in cirrhotic/liver cancer patientsAccess to Roche Diagnostics’ expertise in the UK secured in recognition of Mursla’s differentiated value proposition for liquid biopsy
Mar 11 minMursla presents its new logo to better reflect its core technologyNew logo symbolises the secretion of an exosome from its parental cell along with its markers of origin.
Nov 17, 20214 minMursla announces key appointments to Advisory BoardKey opinion leaders in the fields of exosomes, liquid biopsy and liver disease support Mursla’s ambition
Oct 20, 20213 minMursla granted patents for novel nanoelectronics detection system for exosomesMursla has been granted two patents for its novel nanoelectronics-based sensitive detection method for exosomes.
Jun 15, 20201 minMursla helping on COVID-19Mursla is dedicating resources to help improve COVID-19 diagnostics & therapeutics solutions. We are currently capitalising upon our...
Oct 28, 20191 minCambridge Tech Awards 2019: Mursla among the #OneToWatchMursla was selected again as one of the most exciting tech companies to follow in the Cambridge cluster. https://www.cambridgeindependent...
Mar 12, 20191 minAward for innovation in Cambridgeshire and East of EnglandWe are delighted to have won the #onetowatch award as one of the most innovative companies in Cambridgeshire and East of England. The...